Wednesday, June 10, 2026

pharma Β· Generalized Pustular Psoriasis Β· Schizophrenia Β· VNDA

Vanda Pharmaceuticals Netherlands

Vanda Pharmaceuticals Netherlands clinical programs β€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA Β· NYSE Ticker
Company details
Status
Public
HQ
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
Founded
2003
Employees
600
Programs
60
Drugs
19
Patents
96
Intelligence Β· Clinical Programs

Vanda Pharmaceuticals Netherlands projects

3 ClinicalTrials.gov programs sponsored by Vanda Pharmaceuticals Netherlands.

Vanda Pharmaceuticals Netherlands has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    approved small molecule active

    5 trials
  2. iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Bipolar Disorder

    approved small molecule completed

    1 trial
  3. tasimelteon 20 mg capsule

    Vanda Pharmaceuticals Netherlands B.V.

    Non-24-Hour-Sleep-Wake Disorder

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vanda Pharmaceuticals Netherlands have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.